Topikal Tedaviler

Sanli, Hatice; Kalay Yıldızhan, İncilay

doi:10.4274/turkderm.galenos.2020.20586

Topikal Tedaviler

Hatice ŞANLI, (Ankara Üniversitesi, Tıp Fakültesi, Deri ve Zührevi Hastalıkları Anabilim Dalı, Ankara, Türkiye)

İncilay KALAY YILDIZHAN (Ankara Üniversitesi, Tıp Fakültesi, Deri ve Zührevi Hastalıkları Anabilim Dalı, Ankara, Türkiye)

Türkderm Türk deri hastalıkları ve frengi arşivi

9 0

Yıl: 2020 Cilt: 54 Sayı: 1 Sayfa Aralığı: 23 - 29 Metin Dili: Türkçe DOI: 10.4274/turkderm.galenos.2020.20586 İndeks Tarihi: 14-06-2021

Topikal Tedaviler

Öz:

Topikal tedaviler aknenin patogenezinden sorumlu foliküler hiperkeratinizasyon, bakteriyel kolonizasyon ve enflamasyon gibi basamakların gelişimini önleyerek hafif-orta ya da şiddetli olmak üzere tüm akne lezyonlarının tedavisinde önemli bir yere sahiptirler. Monoterapi, kombinasyon rejimleri ya da sistemik antibiyotiklerle birlikte sıkça kullanılmaktadırlar. Topikal retinoidler, hem enflamatuvar hem de non-enflamatuvar akne lezyonlarının tedavisinde etkin olması nedeni ile birçok akne hastası için birinci basamak tedavi seçeneği olarak önerilmektedir. Topikal antibiyotiklerin bakteriyel direnç gelişim riski nedeni ile monoterapi olarak kullanımlarından kaçınılmalı, kombinasyon tedavilerinde tercih edilmelidir. Benzoil peroksit (BPO), bakteriyel direnci önlemek için hem sistemik hem de topikal antibiyotiklerle kombine olarak sıkça kullanılan, enflamatuvar ve non-enflamatuvar akne lezyonlarında etkili bir ajandır. Akne lezyonların tedavisinin yanı sıra elde edilen remisyonun devamı için özellikle topikal retinoidler, BPO ve azelaik asit idame tedavide önemli bir yere sahiptir.

Anahtar Kelime:

Öz:

Topical therapies have an important place in the treatment of all acne lesions, whether mild to moderate or severe, by way of preventingdevelopment of the steps such as follicular hyperkeratinization, bacterial colonisation, and inflammation that are responsible for the pathogenesisof acne. They are frequently used as a monotherapy, part of combination regimens or with systemic antibiotics. Being effective in the treatmentof both inflammatory and non-inflammatory acne lesions, topical retinoids are recommended as a first line treatment option for many acnepatients. Topical antibiotics should be avoided as monotherapies due to the risk of developing bacterial resistance and should instead beused in combination therapies. Benzoyl peroxide (BPO) is an agent that is effective in inflammatory and noninflammatory acne lesions andis frequently used in combination with both systemic and topical antibiotics to prevent bacterial resistance. Besides in the treatment of acnelesions, topical retinoids, BPO, and azelaic acid in particular have a major role in the maintenance treatment to sustain the remission achieved.

Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

1. Kolli SS, Pecone D, Pona A, Cline A, Feldman SR: Topical Retinoids in Acne Vulgaris. A Systematic Review. Am J Clin Dermatol 2019;20:345-65.
2. Thielitz A, Sidou F, Gollnick H: Control of microcomedone formation throughout a maintenance treatment with adapalene gel, 0.1%. J Eur Acad Dermatol Venereol 2007;21:747-53.
3. Schmidt N, Gans EH: Tretinoin: A Review of Its Anti-inflammatory Properties in the Treatment of Acne. J Clin Aesthet Dermatol 2011;4:22-9.
4. Gollnick H, Abanmi AA, Al-Enezi M, et al: Managing acne in the Middle East: consensus recommendations. J Eur Acad Dermatol Venereol 2017;31:4-35.
5. Thiboutot D, Pariser DM, Egan N, et al: Adapalene gel 0.3% for the treatment of acne vulgaris: a multicenter, randomized, double-blind, controlled, phase III trial. J Am Acad Dermatol 2006;54:242-50.
6. Weiss JS, Shavin JS, Nighland M, Grossman R: Tretinoin microsphere gel 0.1% for photodamaged facial skin: a placebo-controlled trial. Cutis 2006;78:426-32.
7. Phillips TJ: An update on the safety and efficacy of topical retinoids. Cutis 2005;75:14-22.
8. Tan J, Gollnick HP, Loesche C, Ma YM, Gold LS: Synergistic efficacy of adapalene 0.1%-benzoyl peroxide 2.5% in the treatment of 3855 acne vulgaris patients. J Dermatolog Treat 2011;22:197-205.
9. Alexis AF: Clinical considerations on the use of concomitant therapy in the treatment of acne. J Dermatolog Treat 2008;19:199-209.
10. Thiboutot D, Gollnick H, Bettoli V, et al: New insights into the management of acne: an update from the Global Alliance to Improve Outcomes in Acne group. J Am Acad Dermatol 2009;60(5 Suppl):S1-50.
11. Gollnick HP, Bettoli V, Lambert J, et al: A consensus-based practical and daily guide for the treatment of acne patients. J Eur Acad Dermatol Venereol 2016;30:1480-90.
12. Thiboutot DM, Dreno B, Abanmi A, et al: Practical management of acne for clinicians: An international consensus from the Global Alliance to Improve Outcomes in Acne. J Am Acad Dermatol 2018;78(Suppl 1):S1-S23.
13. Tanghetti E, Dhawan S, Green L, et al: Randomized comparison of the safety and efficacy of tazarotene 0.1% cream and adapalene 0.3% gel in the treatment of patients with at least moderate facial acne vulgaris. J Drugs Dermatol 2010;9:549-58.
14. Nast A, Dreno B, Bettoli V, et al: European evidence-based (S3) guidelines for the treatment of acne. J Eur Acad Dermatol Venereol 2012;26:1-29.
15. Thiboutot D, Gold MH, Jarratt MT, et al: Randomized controlled trial of the tolerability, safety, and efficacy of adapalene gel 0.1% and tretinoin microsphere gel 0.1% for the treatment of acne vulgaris. Cutis 2001;68:(Suppl 4)10-9.
16. Thiboutot DM, Weiss J, Bucko A, et al: Adapalene-benzoyl peroxide, a fixeddose combination for the treatment of acne vulgaris: results of a multicenter, randomized double-blind, controlled study. J Am Acad Dermatol 2007;57:791- 9.
17. Gold LS, Tan J, Cruz-Santana A, et al: A North American study of adapalenebenzoyl peroxide combination gel in the treatment of acne. Cutis 2009;84:110- 6.
18. Gollnick HP, Draelos Z, Glenn MJ, et al: Adapalene-benzoyl peroxide, a unique fixed-dose combination topical gel for the treatment of acne vulgaris: a transatlantic, randomized, double-blind, controlled study in 1670 patients. Br J Dermatol 2009;161:1180-9.
19. Cunliffe WJ, Danby FW, Dunlap F, Gold MH, Gratton D, Greenspan A: Randomised, controlled trial of the efficacy and safety of adapalene gel 0.1% and tretinoin cream 0.05% in patients with acne vulgaris. Eur J Dermatol 2002;12:350-4.
20. Thiboutot DM, Shalita AR, Yamauchi PS, et al: Combination therapy with adapalene gel 0.1% and doxycycline for severe acne vulgaris: a multicenter, investigator-blind, randomized, controlled study. Skinmed 2005;4:138-46.
21. Gold LS, Cruz A, Eichenfield L, et al: Effective and safe combination therapy for severe acne vulgaris: a randomized, vehicle-controlled, double-blind study of adapalene 0.1%-benzoyl peroxide 2.5% fixed-dose combination gel with doxycycline hyclate 100 mg. Cutis 2010;85:94-104.
22. Shalita AR, Berson DS, Thiboutot DM, et al: Effects of tazarotene 0.1 % cream in the treatment of facial acne vulgaris: pooled results from two multicenter, double-blind, randomized, vehicle-controlled, parallel-group trials. Clin Ther 2004;26:1865-73.
23. Webster GF, Berson D, Stein LF, Fivenson DP, Tanghetti EA, Ling M: Efficacy and tolerability of once-daily tazarotene 0.1% gel versus once-daily tretinoin 0.025% gel in the treatment of facial acne vulgaris: a randomized trial. Cutis 2001;67(Suppl 6):4-9.
24. Webster GF, Guenther L, Poulin YP, Solomon BA, Loven K, Lee J: A multicenter, double-blind, randomized comparison study of the efficacy and tolerability of once-daily tazarotene 0.1% gel and adapalene 0.1% gel for the treatment of facial acne vulgaris. Cutis 2002;69(Suppl 2):4-11.
25. Shalita AR, Chalker DK, Griffith RF, et al: Tazarotene gel is safe and effective in the treatment of acne vulgaris: a multicenter, double-blind, vehicle-controlled study. Cutis 1999;63:349-54.
26. Bershad S, Kranjac Singer G, Parente JE, et al: Successful treatment of acne vulgaris using a new method: results of a randomized vehicle-controlled trial of short-contact therapy with 0.1% tazarotene gel. Arch Dermatol 2002;138:481- 9.
27. Thiboutot DM, Shalita AR, Yamauchi PS, et al: Adapalene gel, 0.1%, as maintenance therapy for acne vulgaris: a randomized, controlled, investigatorblind follow-up of a recent combination study. Arch Dermatol 2006;142:597- 602.
28. Alirezai M, George SA, Coutts I, et al: Daily treatment with adapalene gel 0.1% maintains initial improvement of acne vulgaris previously treated with oral lymecycline. Eur J Dermatol 2007;17:45-51.
29. Zhang JZ, Li LF, Tu YT, Zheng J: A successful maintenance approach in inflammatory acne with adapalene gel 0.1% after an initial treatment in combination with clindamycin topical solution 1% or after monotherapy with clindamycin topical solution 1%. J Dermatolog Treat 2004;15:372-8.
30. Callender VD, Preston N, Osborn C, Johnson L, Gottschalk RW: A Meta-analysis to Investigate the Relation Between Fitzpatrick Skin Types and Tolerability of Adapalene-Benzoyl Peroxide Topical Gel in Subjects with Mild or Moderate Acne. J Clin Aesthet Dermatol 2010;3:15-9.
31. Thielitz A, Gollnick H: Topical retinoids in acne vulgaris: update on efficacy and safety. Am J Clin Dermatol. 2008;9:369-81.
32. Kaplan YC, Ozsarfati J, Etwel F, Nickel C, Nulman I, Koren G: Pregnancy outcomes following first-trimester exposure to topical retinoids: a systematic review and meta-analysis. Br J Dermatol 2015;173:1132-41.
33. Del Rosso JQ, Leyden JJ, Thiboutot D, Webster GF: Antibiotic use in acne vulgaris and rosacea: clinical considerations and resistance issues of significance to dermatologists. Cutis 2008;82:5-12.
34. Zaenglein AL, Pathy AL, Schlosser BJ, et al: Guidelines of care for the management of acne vulgaris. J Am Acad Dermatol 2016;74:945-73.
35. Jacobs A, Starke G, Rosumeck S, Nast A: Systematic review on the rapidity of the onset of action of topical treatments in the therapy of mild-to-moderate acne vulgaris. Br J Dermatol 2014;170:557-64.
36. Bowe WP, Shalita AR: Effective over-the-counter acne treatments. Semin Cutan Med Surg 2008;27:170-6.
37. Minciullo PL, Patafi M, Giannetto L, et al: Allergic contact angioedema to benzoyl peroxide. J Clin Pharm Ther 2006;31:385-7.
38. Stinco G, Bragadin G, Trotter D, Pillon B, Patrone P: Relationship between sebostatic activity, tolerability and efficacy of three topical drugs to treat mild to moderate acne. J Eur Acad Dermatol Venereol 2007;21:320-5.
39. Korkut C, Piskin S: Benzoyl peroxide, adapalene, and their combination in the treatment of acne vulgaris. J Dermatol 2005;32:169-73.
40. Webster G, Rich P, Gold MH, Mraz S, Calvarese B, Chen D: Efficacy and tolerability of a fixed combination of clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel in moderate or severe acne subpopulations. J Drugs Dermatol 2009;8:736-43.
41. Fagundes DS, Fraser JM, Klauda HC: New therapy update--A unique combination formulation in the treatment of inflammatory acne. Cutis 2003;72:16-9.
42. Zouboulis CC, Fischer TC, Wohlrab J, Barnard J, Alió AB: Study of the efficacy, tolerability, and safety of 2 fixed-dose combination gels in the management of acne vulgaris. Cutis 2009;84:223-9.
43. Eady EA, Farmery MR, Ross JI, et al. Effects of benzoyl peroxide and erythromycin alone and in combination against antibiotic-sensitive and -resistant skin bacteria from acne patients. Br J Dermatol 1994;131:331-6.
44. Glass D, Boorman GC, Stables GI, Cunliffe WJ, Goode K: A placebo-controlled clinical trial to compare a gel containing a combination of isotretinoin (0.05%) and erythromycin (2%) with gels containing isotretinoin (0.05%) or erythromycin (2%) alone in the topical treatment of acne vulgaris. Dermatology 1999;199:242-7.
45. Stein Gold LF, Jarratt MT, Bucko AD, et al: Efficacy and Safety of Once-Daily Dapsone Gel, 7.5% for Treatment of Adolescents and Adults With Acne Vulgaris: First of Two Identically Designed, Large, Multicenter, Randomized, Vehicle-controlled Trials. J Drugs Dermatol 2016;15:553-61.
46. Eichenfield LF, Lain T, Frankel EH, et al: Efficacy and Safety of OnceDaily Dapsone Gel, 7.5% for Treatment of Adolescents and Adults With Acne Vulgaris: Second of Two Identically Designed, Large, Multicenter, Randomized, Vehicle-Controlled Trials. J Drugs Dermatol 2016;15:962-9.
47. Adisen E, Kaymak Y, Gurer MA, Durukan E: Topical tetracycline in the treatment of acne vulgaris. J Drugs Dermatol 2008;7:953-5.
48. Tunca M, Akar A, Ozmen I, Erbil H: Topical nadifloxacin 1% cream vs. topical erythromycin 4% gel in the treatment of mild to moderate acne. Int J Dermatol 2010;49:1440-4.
49. Choudhury S, Chatterjee S, Sarkar DK, Dutta RN: Efficacy and safety of topical nadifloxacin and benzoyl peroxide versus clindamycin and benzoyl peroxide in acne vulgaris: A randomized controlled trial. Indian J Pharmacol 2011;43:628-31.
50. Gollnick HP, Graupe K, Zaumseil RP: [Azelaic acid 15% gel in the treatment of acne vulgaris. Combined results of two double-blind clinical comparative studies]. J Dtsch Dermatol Ges 2004;2:841-7.
51. Gollnick HP, Graupe K, Zaumseil RP: Comparison of combined azelaic acid cream plus oral minocycline with oral isotretinoin in severe acne. Eur J Dermatol 2001;11:538-44.
52. Graupe K, Cunliffe WJ, Gollnick HP, Zaumseil RP: Efficacy and safety of topical azelaic acid (20 percent cream): an overview of results from European clinical trials and experimental reports. Cutis 1996;57:20-35.
53. Zander E, Weisman S. Treatment of acne vulgaris with salicylic acid pads. Clin Ther 1992;14:247-53.
54. Tarimci N, Sener S, Kilinc T. Topical sodium sulfacetamide/sulfur lotion. J Clin Pharm Ther 1997;22:301.

APA	Sanli H, Kalay Yıldızhan İ (2020). Topikal Tedaviler. , 23 - 29. 10.4274/turkderm.galenos.2020.20586
Chicago	Sanli Hatice,Kalay Yıldızhan İncilay Topikal Tedaviler. (2020): 23 - 29. 10.4274/turkderm.galenos.2020.20586
MLA	Sanli Hatice,Kalay Yıldızhan İncilay Topikal Tedaviler. , 2020, ss.23 - 29. 10.4274/turkderm.galenos.2020.20586
AMA	Sanli H,Kalay Yıldızhan İ Topikal Tedaviler. . 2020; 23 - 29. 10.4274/turkderm.galenos.2020.20586
Vancouver	Sanli H,Kalay Yıldızhan İ Topikal Tedaviler. . 2020; 23 - 29. 10.4274/turkderm.galenos.2020.20586
IEEE	Sanli H,Kalay Yıldızhan İ "Topikal Tedaviler." , ss.23 - 29, 2020. 10.4274/turkderm.galenos.2020.20586
ISNAD	Sanli, Hatice - Kalay Yıldızhan, İncilay. "Topikal Tedaviler". (2020), 23-29. https://doi.org/10.4274/turkderm.galenos.2020.20586

APA	Sanli H, Kalay Yıldızhan İ (2020). Topikal Tedaviler. Türkderm Türk deri hastalıkları ve frengi arşivi, 54(1), 23 - 29. 10.4274/turkderm.galenos.2020.20586
Chicago	Sanli Hatice,Kalay Yıldızhan İncilay Topikal Tedaviler. Türkderm Türk deri hastalıkları ve frengi arşivi 54, no.1 (2020): 23 - 29. 10.4274/turkderm.galenos.2020.20586
MLA	Sanli Hatice,Kalay Yıldızhan İncilay Topikal Tedaviler. Türkderm Türk deri hastalıkları ve frengi arşivi, vol.54, no.1, 2020, ss.23 - 29. 10.4274/turkderm.galenos.2020.20586
AMA	Sanli H,Kalay Yıldızhan İ Topikal Tedaviler. Türkderm Türk deri hastalıkları ve frengi arşivi. 2020; 54(1): 23 - 29. 10.4274/turkderm.galenos.2020.20586
Vancouver	Sanli H,Kalay Yıldızhan İ Topikal Tedaviler. Türkderm Türk deri hastalıkları ve frengi arşivi. 2020; 54(1): 23 - 29. 10.4274/turkderm.galenos.2020.20586
IEEE	Sanli H,Kalay Yıldızhan İ "Topikal Tedaviler." Türkderm Türk deri hastalıkları ve frengi arşivi, 54, ss.23 - 29, 2020. 10.4274/turkderm.galenos.2020.20586
ISNAD	Sanli, Hatice - Kalay Yıldızhan, İncilay. "Topikal Tedaviler". Türkderm Türk deri hastalıkları ve frengi arşivi 54/1 (2020), 23-29. https://doi.org/10.4274/turkderm.galenos.2020.20586